UQ Still Forging Ahead With Clamp Technology Vaccine

  • Context: COVID 
  • Thread starter Thread starter bhobba
  • Start date Start date
  • Tags Tags
    Technology Vaccine
Click For Summary
SUMMARY

The University of Queensland (UQ) has advanced its clamp technology for vaccine development, overcoming previous issues with false positives in HIV tests. The re-engineered version, named Clamp2, is set for human trials in early 2024, backed by an $8.5 million investment from CEP. Preclinical tests indicate that Clamp2 produces stabilized antigens and elicits strong neutralizing immune responses across various virus families, including influenza, Nipah, and SARS-CoV-2. The vaccine will be manufactured at UQ's National Biologics Facility, emphasizing the importance of establishing a rapid response vaccine pipeline for future pandemics.

PREREQUISITES
  • Understanding of vaccine technology and development processes
  • Familiarity with preclinical testing methodologies
  • Knowledge of immunology, specifically neutralizing immune responses
  • Awareness of pandemic preparedness strategies
NEXT STEPS
  • Research the specifics of the Clamp2 vaccine platform and its applications
  • Explore the role of the National Biologics Facility in vaccine production
  • Investigate the implications of rapid response vaccine pipelines for public health
  • Learn about the mechanisms of neutralizing antibodies in vaccine efficacy
USEFUL FOR

This discussion is beneficial for vaccine researchers, public health officials, and professionals involved in pandemic preparedness and vaccine technology development.

bhobba
Mentor
Insights Author
Messages
10,970
Reaction score
3,839
Precis of a news report from today's Courier Mail.

The University of Queensland clamp technology knocked out because it gave false positives to HIV tests is set for human trials early next year. Scientists have re-engineered the clamp, dubbed Clamp2, so there is no diagnostic interference. CEP provided $8.5m to support the development of the improved technology.

The Clamp2 vaccine will be manufactured at the National Biologics Facility at UQ.

Keith Chappell, UQ’s Rapid Response Vaccine co-leader, said preclinical testing has shown the Clamp2 platform was meeting all expectations, producing stabilised antigens and inducing strong neutralising immune responses. “We have validated the Clamp2 platform in the laboratory. It is equivalent to the original vaccine across multiple virus families, including the influenza virus, Nipah virus and SARS- CoV-2.

Professor Dan Watterson, who spearheaded the successful Clamp2 redesign, said it was important for people to understand the ultimate aim was not to rush a new Covid vaccine to market. “This is about the role this technology could play in safeguarding against future pandemics and ensuring we have an Australian-based rapid response vaccine pipeline.

Thanks
Bill
 
Reply
  • Like
Likes   Reactions: atyy, pinball1970 and BillTre
Biology news on Phys.org
That's great!
 
Reply
  • Like
Likes   Reactions: bhobba